Nippon Chemiphar
4539.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥24.4bn | ¥23.5bn | ¥22.4bn | ¥22.0bn | ¥24.0bn | ¥24.4bn |
| Operating income | ¥284m | ¥86m | −¥1.0bn | −¥1.4bn | −¥355m | ¥286m |
| Ordinary income | ¥369m | ¥339m | −¥1.0bn | −¥983m | −¥2m | ¥690m |
| Total assets | ¥32.7bn | ¥33.1bn | ¥34.9bn | ¥35.9bn | ¥35.1bn | ¥34.6bn |
| Net assets / equity | ¥9.8bn | ¥9.4bn | ¥9.4bn | ¥10.3bn | ¥11.0bn | ¥11.1bn |
| EPS (basic) | ¥82.61 | ¥39.33 | ¥-212.84 | ¥-95.59 | ¥68.32 | ¥176.96 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 203 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 203 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 203 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Medicine | ¥31.9bn | ¥187m |
| Other segments | ¥1.2bn | −¥7m |
| Adjustments & eliminations | — | — |
| Total | ¥33.1bn | ¥179m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.